Journal article 290 views 75 downloads
Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia
Patrícia Amaral,
Rhona Christie 
,
Daisy O. F. Gresham,
Emma Lucas,
Luyao Kevin Xu,
Lena Behrmann ,
Jonathan Bond,
Sofie Degerman ,
Frederik W. van Delft ,
Steven Goossens ,
Melanie Hagleitner,
Chris Halsey ,
Nick Jones ,
Tim Lammens ,
Frank N. van Leeuwen ,
Marc R. Mansour ,
Panagiotis Ntziachristos ,
David O’Connor,
João T. Barata
,
Daisy O. F. Gresham,
Emma Lucas,
Luyao Kevin Xu,
Lena Behrmann ,
Jonathan Bond,
Sofie Degerman ,
Frederik W. van Delft ,
Steven Goossens ,
Melanie Hagleitner,
Chris Halsey ,
Nick Jones ,
Tim Lammens ,
Frank N. van Leeuwen ,
Marc R. Mansour ,
Panagiotis Ntziachristos ,
David O’Connor,
João T. Barata
Leukemia
Swansea University Authors:
Emma Lucas, Nick Jones
-
PDF | Accepted Manuscript
Author accepted manuscript document released under the terms of a Creative Commons CC-BY licence using the Swansea University Research Publications Policy (rights retention).
Download (9.56MB)
DOI (Published version): 10.1038/s41375-025-02723-2
Abstract
Underlying biology, challenges and emergent concepts in the treatment of relapsed and refractory pediatric T-cell acute lymphoblastic leukemia
| Published in: | Leukemia |
|---|---|
| ISSN: | 0887-6924 1476-5551 |
| Published: |
Springer Science and Business Media LLC
2025
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa70230 |
| College: |
Faculty of Medicine, Health and Life Sciences |
|---|---|
| Funders: |
The work related to this review has been funded by the following grants: FKC/ATG4TALL/2023 from the FIGHT KIDS CANCER Program of the European Science Foundation (to FvL, LB, JB, SD, FWvD, SG, CH, DOC and JTB); WWCR 24-0426 from Worldwide Cancer Research, UK (to JTB); 21717 from Programa Gilead GÉNESE, Gilead, Portugal (to JTB); PTDC/MEC-ONC/4606/2021 from Fundação para a Ciência e a Tecnologia, Portugal (to JTB); CCLGA 2020 24 (to CH), CCLGA 2021 05 and CCLGA 2024 08 (to NJ), and CCLGA 2022 20 (to FWvD) from the Children’s Cancer and Leukaemia Group (CCLG) Little Princess Trust; PR2021-0049 from the Swedish Childhood Cancer Foundation (to SD); 24 3490 Pj from the Swedish Cancer Society (to SD); AMP 24-1152 from the Cancer Research Foundation in Northern Sweden (to SD); 20/FFP-P/8844 from Science Foundation Ireland (to JB); 18/SPP/3522 from Science Foundation Ireland together with Children’s Health Ireland (to JB); S002322 and G0A2722N from Research Foundation Flanders (FWO), Flanders, Belgium (to SG); G0F4721N and G0A8B24N from FWO (to PN); F/2024/2666 from the Foundation Against Cancer (to PN); and GN2709 from Action Medical Research (to FWvD); and also by the following awards: DRCPFA-Nov21\100001 from Cancer Research UK Programme Foundation (to CH and RC); A-18-3 from the National Children’s Research Centre/ Children’s Health Foundation Leadership (to JB). TL is supported by Kinderkankerfonds; JTB is funded also by a Breakthrough Idea Grant from GIMM. PN is funded also by start-up funds from the Department of Biomolecular Medicine, Ghent University, a Flanders interuniversity consortium grant (BOF.IBO.2023.0006.02) and a Cancer Research Institute Ghent (CRIG) partnership grant. FWvD is funded also by JGW Patterson Foundation. MRM is funded through a Great Ormond Street Children’s Charity Professorship. DOFG is funded through the Great Ormond Street Children’s Charity. |